Skip to ContentSkip to Navigation
How to find us dr. T. van Meerten

Publications

Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment

Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands

Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study

Molecular imaging in lymphoma beyond F-18-FDG-PET: understanding the biology and its implications for diagnostics and therapy

WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis

CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

Read more

Press/media

UMCG gaat zelf medicijn tegen lymfeklierkanker maken

Gronings ziekenhuis gaat prijzig kankermedicijn zelf maken met miljoenensubsidie

€ 30 miljoen subsidie voor UMCG-onderzoek naar veelbelovende kankerbehandeling

Wanneer milieuwetgeving de strijd tegen kanker hindert

Doorbraak in behandeling lymfeklierkanker

Read more